Connect with us

Hi, what are you looking for?

Jewish Business News


Israeli Groundbreaking Development Allows Cannabis to be Transferred Directly to the Brain

The development allows the transfer of cannabis molecules to penetrate into the brain through the blood-brain barrier, which stops the entry of many substances.

Technology developed at the Technion enabled the Israeli cannabis-based pharmaceutical company Nextage to completed a development that allows the transfer of cannabis molecules directly into the brain.  The molecules penetrate the brain through the blood-brain barrier, which stops the entry of many substances.

The technology allows for the avoidance of side effects and dose reductions for patients and has enormous potential in dealing with brain diseases. Most of the active ingredients that are currently on the market, do not cross the blood-brain barrier, and can create significant side effects in the rest of the body.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

The company says it will begin licensing contacts for companies interested in developing system-based brain disease drugs. Nextage also announced it will file a patent application based on information gathered during the development.

The passage of drugs through the blood-brain barrier is an essential challenge for the world of research and currently remains without a complete solution. Finding a solution to cross the blood-brain barrier is a groundbreaking achievement in the global pharmaceutical industry. The development of the formulation included: adapting the technology for use with CBD, optimizing the composition of the technology for the benefit of use with cannabinoids, and determining the maximum load capacity of the cannabinoids.

During pre-clinical trials conducted so far, it has been found that the technology can transmit a wide range of substances of various types through the blood-brain barrier directly. It can do that without any dispersion of the substances in other organs in the body while maintaining the active substance activity and significantly reducing side effects.

It is also possible that the direct transfer will allow for a significant increase in bioavailability and as a result, there may be a reduction in the dose given to patients.

The field of brain and central nervous system diseases is one of the major challenges of the pharmaceutical industry in recent years. Diseases including Parkinson’s, Alzheimer’s, epilepsy, chronic pain, brain cancer, and various psychiatric can benefit from the new development.




You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.